With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
The current price of Novo Nordisk A/S in the market is $41.11, with a 24-hour trading volume of $837.59M. The asset's market cap is $182.36B, after moving 6.75% in the last day.
Tokenized Novo Nordisk A/S is trading at $41.93, with a tokenized market cap of $3.43M and a 24-hour trading volume of $904.36K. The tokenized asset has moved 8.43% in the past 24 hours.